title: [Novel strategies of ovarian cancer treatment].
abstract: Ovarian cancer is the most lethal gynecological malignancy. Due to scarce specific symptoms, women usually seek medical help once the disease is highly advanced, with distant metastases. Currently no screening is available, making this particular cancer hard to detect in the early stage. Standard treatment is insufficient for many patients, especially in the recurrent disease. This fact explains the tremendous need to search for novel therapeutic approaches. Inhibition of angiogenesis and destruction of cancer stem cells are attempts that affect the tumor microenvironment. There is a lot of potential in inhibiting poly(ADP-rybose)polymerase (PARP) or I class histone deacetylase. Drug repositioning may also be beneficial, as it gives old drugs new purposes. Metformin, a well-known antidiabetic agent, is an example of this phenomenon. Constant progress in medicine and science makes us hope for positive outcomes while treating this highly dangerous disease.
authors.affiliation: Silesian University of Medicine in Katowice, Poland: Department of Internal Diseases and Clinical Pharmacology.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Duda
authors.affiliation: Silesian University of Medicine in Katowice, Poland: Department of Internal Diseases and Clinical Pharmacology.
authors.forename: Hanna
authors.initials: H
authors.lastname: Cholewa
authors.affiliation: Silesian University of Medicine in Katowice, Poland: Department of Internal Diseases and Clinical Pharmacology.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Łabuzek
authors.affiliation: Silesian University of Medicine in Katowice, Poland: Chair of Oncology and Radiotherapy, Department of Oncology.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Boratyn-Nowicka
authors.affiliation: Silesian University of Medicine in Katowice, Poland: Department of Internal Diseases and Clinical Pharmacology.
authors.forename: Bogusław
authors.initials: B
authors.lastname: Okopień
mesh_terms: D005260:Female; D006801:Humans; D008687:Metformin / Q000627:therapeutic use; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use*
chemical_list: D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D008687:Metformin
keywords: angiogenesis inhibitors; histone deace tylase inhibitors; metformin; ovarian cancer; poly(ADP-ribose) polymerases